Mostrar el registro sencillo del ítem

Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply

dc.contributor.authorBernal del Castillo, Teresa 
dc.contributor.authorMartínez Camblor, Pablo 
dc.contributor.authorSánchez García, Joaquín
dc.contributor.authorSanz, Guillermo
dc.date.accessioned2016-06-21T11:37:19Z
dc.date.available2016-06-21T11:37:19Z
dc.date.issued2016
dc.identifier.citationLeukemia, 30(3), p. 740-741 (2016); doi:10.1038/leu.2015.339
dc.identifier.issn0887-6924
dc.identifier.issn1476-5551
dc.identifier.urihttp://hdl.handle.net/10651/37907
dc.format.extentp. 740-741
dc.language.isoeng
dc.relation.ispartofLeukemia
dc.rights© 2016 Macmillan Publishers Limited
dc.sourceWOS:000371688500025
dc.titleEffectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply
dc.typejournal article
dc.identifier.doi10.1038/leu.2015.339
dc.relation.publisherversionhttp://dx.doi.org/10.1038/leu.2015.339
dc.rights.accessRightsopen access


Ficheros en el ítem

untranslated

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem